Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial
Conditions
Advanced Fallopian Tube Carcinoma · Advanced Fallopian Tube High Grade Serous Adenocarcinoma · Advanced Ovarian Carcinoma · Advanced Ovarian Carcinosarcoma · Advanced Ovarian Clear Cell Adenocarcinoma · Advanced Ovarian Endometrioid Adenocarcinoma · Advanced Ovarian High Grade Serous Adenocarcinoma · Advanced Primary Peritoneal Carcinoma · Advanced Primary Peritoneal High Grade Serous Adenocarcinoma · Fallopian Tube Carcinosarcoma · Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Endometrioid Adenocarcinoma · FIGO Stage III Ovarian Cancer 2014 · FIGO Stage IV Ovarian Cancer 2014 · Ovarian Mixed Cell Adenocarcinoma · Primary Peritoneal Carcinosarcoma · Primary Peritoneal Clear Cell Adenocarcinoma · Primary Peritoneal Endometrioid Adenocarcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015Contact: Principal Investigator (Nina J. Karlin, MD)Mayo Clinic in Florida, Jacksonville, Florida, United States
Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015Contact: Principal Investigator (Gerardo Colon-Otero, MD)Mayo Clinic in Rochester, Rochester, Minnesota, United States
Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015Contact: Principal Investigator (Matthew S. Block, MD, PhD)
Study leads
Matthew S. Block, MD, PhD
Principal Investigator
Mayo Clinic in Rochester